PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
PBYI on Nasdaq
Shares outstanding
49,633,071
Price per share
$6.09
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
35,344,888
Total reported value
$210,177,586
% of total 13F portfolios
0%
Share change
+745,293
Value change
+$5,315,905
Number of holders
150
Price from insider filings
$6.09
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ACORN BIOVENTURES, L.P. 8% +19% $11,859,557 +$1,988,442 3,940,052 +20% Anders Hove 31 Dec 2024
BlackRock, Inc. 5.6% $8,366,151 2,779,452 BlackRock, Inc. 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 3.9% $5,701,319 1,894,126 Millennium Management LLC 31 Dec 2024

As of 31 Dec 2025, 150 institutional investors reported holding 35,344,888 shares of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI). This represents 71% of the company’s total 49,633,071 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ACORN CAPITAL ADVISORS, LLC 8.3% 4,131,299 0% 8.3% $24,581,229
VANGUARD GROUP INC 7.7% 3,797,748 +2.9% 0% $22,596,600
BlackRock, Inc. 7.3% 3,642,588 +1.8% 0% $21,673,399
RENAISSANCE TECHNOLOGIES LLC 4.3% 2,123,813 -1.3% 0.02% $12,636,687
ACADIAN ASSET MANAGEMENT LLC 4.1% 2,024,823 -1.4% 0.02% $12,043,000
AMERICAN CENTURY COMPANIES INC 3.3% 1,650,137 +11% 0% $9,818,315
DIMENSIONAL FUND ADVISORS LP 2.7% 1,339,603 +5.3% 0% $7,971,040
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 2.3% 1,120,329 +35% 0.04% $6,665,958
GEODE CAPITAL MANAGEMENT, LLC 2% 994,345 +1.1% 0% $5,917,285
STATE STREET CORP 1.8% 877,077 +17% 0% $5,218,608
Connor, Clark & Lunn Investment Management Ltd. 1.8% 875,301 -7.2% 0.01% $5,208,041
KENNEDY CAPITAL MANAGEMENT LLC 1.7% 868,315 +0.08% 0.11% $5,166,474
GOLDMAN SACHS GROUP INC 1.6% 793,962 +238% 0% $4,724,074
BRIDGEWAY CAPITAL MANAGEMENT, LLC 1.6% 773,485 +78% 0.1% $4,602,236
RITHOLTZ WEALTH MANAGEMENT 1.4% 694,001 +47% 0.08% $4,129,306
AQR CAPITAL MANAGEMENT LLC 1.3% 666,605 +410% 0% $3,966,300
NORTHERN TRUST CORP 1.2% 616,197 +17% 0% $3,666,372
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.1% 547,853 +18% 0% $3,259,725
GLOBEFLEX CAPITAL L P 0.91% 452,606 0% 0.41% $2,693,006
SEI INVESTMENTS CO 0.87% 429,925 +24% 0% $2,558,037
LSV ASSET MANAGEMENT 0.82% 404,802 -28% 0.01% $2,409,000
D. E. Shaw & Co., Inc. 0.76% 378,296 -24% 0% $2,250,861
Bank of New York Mellon Corp 0.71% 351,881 -0.98% 0% $2,093,693
MORGAN STANLEY 0.66% 326,774 -14% 0% $1,944,305
PRUDENTIAL FINANCIAL INC 0.58% 286,509 +30% 0% $1,704,729

Institutional Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 35,344,888 $210,177,586 +$5,315,905 $5.95 150
2025 Q3 34,391,735 $182,593,849 +$11,523,900 $5.31 132
2025 Q2 32,782,327 $112,437,236 +$8,596,760 $3.43 121
2025 Q1 30,413,709 $90,020,693 +$2,952,602 $2.96 116
2024 Q4 29,394,127 $89,648,308 -$7,801,084 $3.05 111
2024 Q3 29,741,414 $75,860,432 -$5,784,759 $2.55 100
2024 Q2 30,964,332 $100,942,686 -$1,236,662 $3.26 98
2024 Q1 29,743,016 $157,668,204 +$17,052,475 $5.30 93
2023 Q4 26,608,129 $115,214,198 +$4,767,738 $4.33 82
2023 Q3 25,704,166 $67,598,924 -$2,428,856 $2.63 67
2023 Q2 26,576,438 $93,807,644 -$4,382,380 $3.53 67
2023 Q1 27,855,345 $86,065,002 -$527,663 $3.09 77
2022 Q4 27,496,427 $116,318,396 -$138,759 $4.23 86
2022 Q3 27,643,484 $65,508,451 -$1,989,453 $2.37 71
2022 Q2 27,896,143 $79,494,556 -$4,139,901 $2.85 77
2022 Q1 29,904,506 $86,071,643 -$477,483 $2.88 95
2021 Q4 30,286,741 $92,179,926 -$39,504,988 $3.04 96
2021 Q3 32,161,600 $225,498,183 -$28,665,006 $7.01 112
2021 Q2 34,758,681 $319,233,355 -$17,282,962 $9.18 118
2021 Q1 36,622,682 $355,897,814 +$13,747,740 $9.72 117
2020 Q4 35,303,327 $362,460,750 -$9,270,334 $10.26 120
2020 Q3 38,674,035 $390,198,466 +$12,930,607 $10.09 128
2020 Q2 35,087,132 $365,869,787 -$6,707,284 $10.43 124
2020 Q1 36,622,300 $308,895,684 +$43,630,089 $8.44 121
2019 Q4 31,346,607 $274,240,276 -$64,624,795 $8.75 129
2019 Q3 36,566,451 $393,738,047 +$16,141,553 $10.77 138
2019 Q2 34,765,202 $441,844,355 -$103,904,681 $12.71 132
2019 Q1 34,161,633 $1,323,863,060 +$17,647,411 $38.79 156
2018 Q4 35,195,489 $716,303,054 -$227,829,815 $20.35 137
2018 Q3 35,649,697 $1,634,461,087 -$26,392,843 $45.85 154
2018 Q2 35,935,120 $2,125,191,869 -$1,056,901 $59.15 169
2018 Q1 35,574,353 $2,419,811,616 -$81,238,705 $68.05 168
2017 Q4 36,157,207 $3,573,656,170 -$112,228,539 $98.85 194
2017 Q3 36,681,359 $4,391,736,256 +$169,794,588 $119.75 170
2017 Q2 35,525,549 $3,104,620,640 +$57,539,772 $87.40 152
2017 Q1 37,964,211 $1,412,435,790 +$191,118,200 $37.20 135
2016 Q4 34,931,958 $1,072,410,439 +$72,943,477 $30.70 128
2016 Q3 29,992,904 $2,010,275,475 +$5,538,941 $67.05 145
2016 Q2 31,810,369 $947,699,404 +$39,640,223 $29.79 107
2016 Q1 30,412,423 $892,904,817 -$134,999,214 $29.37 114
2015 Q4 32,269,617 $2,529,775,949 +$177,573,758 $78.40 131
2015 Q3 30,151,475 $2,271,836,092 -$40,738,025 $75.36 159
2015 Q2 30,442,694 $3,553,611,040 -$40,063,235 $116.75 193
2015 Q1 29,120,599 $6,873,292,525 +$477,852,182 $236.11 194
2014 Q4 27,148,671 $5,140,326,488 +$68,524,432 $189.27 183
2014 Q3 26,680,747 $6,365,417,896 +$471,513,554 $238.57 182
2014 Q2 25,372,332 $1,674,353,490 -$43,122,202 $66.00 132
2014 Q1 25,068,536 $2,610,636,453 +$107,147,987 $104.14 130